Engineers at Google have developed Gemini Robotics 1.5, a novel AI-driven robot that employs an adjustable 'thinking budget' to pause and evaluate optimal strategies before acting. It integrates human-like reasoning with continuous cross-embodiment learning, allowing knowledge to propagate instantly between units and drive exponential performance improvements across diverse industrial and service applications.
Key points
Adjustable thinking budget enables robots to allocate time for planning and reasoning before executing tasks.
Cross-embodiment learning synchronizes knowledge updates across all units in real time, accelerating collective intelligence.
Continuous online learning and integrated safety gating yield robust, adaptable robotic agents for complex environments.
Why it matters:
This breakthrough marks a shift from task automation to intelligence automation, enabling adaptable, scalable robots that can tackle novel challenges with human-like reasoning.
Q&A
What is the 'thinking budget'?
How does cross-embodiment learning work?
How is safety ensured in Gemini Robotics 1.5?
How can developers access Gemini Robotics 1.5?
Read full article
Academy
Artificial Intelligence in Longevity Science
Artificial Intelligence is a set of computational techniques that enable machines to perform tasks requiring human-like intelligence. In the field of longevity science, AI algorithms can analyze large datasets from genomics, clinical trials, and lifestyle studies to identify patterns associated with aging and age-related diseases. Researchers use machine learning models to predict biological age, identify biomarkers of aging, and uncover novel therapeutic targets. By integrating diverse data sources, AI helps scientists prioritize research directions, optimize experimental design, and accelerate the discovery of interventions that promote healthy lifespan extension.
One common approach in longevity research is supervised learning, where models are trained on labeled datasets to recognize features linked to youth or age-related decline. Techniques such as decision trees, random forests, and gradient boosting can classify samples based on gene expression profiles or metabolic signatures. Another key method is unsupervised learning, which clusters data without predefined labels, enabling the discovery of new biological subtypes or patient cohorts. Techniques like k-means clustering and hierarchical modeling help researchers uncover hidden relationships in large-scale datasets.
Deep learning, a specialized form of machine learning, leverages neural networks with multiple layers to model complex, non-linear relationships between variables. Convolutional neural networks (CNNs) excel at analyzing images from histopathology or cellular microscopy, revealing morphological features associated with aging. Recurrent neural networks (RNNs) and transformer models process temporal sequences such as longitudinal health records or wearable device measurements, capturing dynamic changes over time. These deep learning models can forecast health trajectories, detect early signs of disease, and suggest personalized interventions.
Predictive modeling is crucial for identifying individuals at high risk of age-related conditions, including cardiovascular disease, neurodegeneration, and metabolic disorders. By training algorithms on large cohorts with known outcomes, AI can estimate an individual’s probability of developing a specific disease within a given timeframe. This enables clinicians to implement preventive strategies earlier, tailor treatment plans, and monitor patient responses to therapies. AI-driven risk scores can also inform public health policies by predicting population-level trends and resource needs.
In drug discovery and repurposing, AI models screen vast libraries of chemical compounds to find candidates that modulate aging-related pathways. Machine learning techniques predict molecular interactions, optimize compound properties, and assess potential toxicity profiles. AI can repurpose existing drugs by analyzing their mechanisms and matching them to targets implicated in aging. This accelerates the path to clinical trials and reduces the cost of developing new geroprotective therapies. Collaborative platforms combine AI predictions with experimental validation to refine candidate selection.
Beyond data analysis and modeling, AI-powered robotics and automation systems support high-throughput experimentation in longevity laboratories. Robotic platforms equipped with computer vision and intelligent planning handle tasks such as cell culture, compound dosing, and real-time monitoring of cellular responses. This reduces manual labor, increases reproducibility, and expands the scale of screening assays. By integrating AI-driven robotics with laboratory information management systems, researchers can design adaptive experiments that learn from interim results and adjust protocols accordingly.
As the field evolves, ethical considerations play a critical role in the responsible application of AI in longevity science. Ensuring data privacy, addressing algorithmic bias, and promoting equitable access to AI-driven therapies are essential to maximize societal benefit. Ongoing collaborations between computational scientists, biologists, and ethicists aim to establish guidelines and standards that foster transparency, reproducibility, and patient trust. By combining cutting-edge AI methods with rigorous scientific practices, longevity research can move closer to unlocking the secrets of healthy aging for all.
